Lundbeck (HLUN-B.CO)

Executive Summary

Lundbeck is a Danish biopharmaceutical company with over a century of experience in developing therapies for brain diseases. The company's portfolio includes commercial products such as Trintellix (vortioxetine) for major depressive disorder and Rexulti (brexpiprazole) for schizophrenia and agitation associated with Alzheimer's disease. While facing generic competition in mature markets, Lundbeck continues to invest in its pipeline, with a focus on CNS disorders. The company's most advanced novel pipeline asset is Lu AG13909, a potential treatment for congenital adrenal hyperplasia (CAH), currently in a Phase 1/2 trial (NCT05669950) with estimated completion in 2027. Lundbeck's strategy includes expanding indications for existing products and pursuing internal R&D in neurology and psychiatry. With a market cap of approximately $43 billion, the company is positioned as a specialized player in brain health, though near-term growth catalysts are limited pending pipeline progress. The company's revenue is supported by its established product base, but its long-term trajectory depends on successful clinical development and regulatory approvals.

Upcoming Catalysts (preview)

• 2027Lu AG13909 Phase 1/2 data readout for Congenital Adrenal Hyperplasia40% success